Latest news with #HeartRhythmSociety
Medscape
02-06-2025
- Business
- Medscape
Same-Day Discharge Criteria Outlined for AF Ablation
SAN DIEGO — Same-day discharge after ablation of atrial fibrillation (AF) is an appropriate strategy for saving costs if performed with strict selection criteria and protocols, according to a recently issued joint statement from the American College of Cardiology and the Heart Rhythm Society. Same-day discharge has long been indicated for catheter ablations to abort routine atrial flutter, atrioventricular nodal reentrant tachycardia, and focal atrial tachycardias, according to the authors of the new joint statement. Although they maintained patients selected for elective catheter ablation of AF require heightened scrutiny, they endorsed same-day AF ablation when used selectively. The statement evaluates 'evidence supporting shorter hospitalization stay with same-day discharge for intracardiac ablations agonistic to site of care,' reported Amit J. Shankar, MD , an electrophysiologist with Canton-Potsdam Hospital in Potsdam, New York, who served as a representative for the Heart Rhythm Society in developing the statement. Whether in a hospital setting or an outpatient facility, the statement describes same-day discharge ablation as an opportunity to improve patient access, improve efficiency, and reduce healthcare costs. The adoption of same-day discharge after AF ablation was accelerated during the COVID-19 pandemic, said Samuel O. Jones, MD, a cardiologist affiliated with The Chattanooga Heart Institute in Chattanooga, Tennessee, and a fellow of the American College of Cardiology. 'Improved workflows, technological innovations, and procedure advancements have also contributed to the high rates at which these are performed,' added Jones, who helped write the statement. The statement was released on April 24 to coincide with the first day of the Heart Rhythm Society (HRS) 2025 annual scientific meeting. It was simultaneously published in Heart Rhythm and the Journal of the American College of Cardiology . The scientific statement's recommendation is intended for elective rather than urgent or emergency ablations. Support for the statement was drawn from multiple case-controlled studies, meta-analyses, and outcome databases. In one example, a 12-study meta-analysis with data from more than 18,000 elective ablations showed no significant differences in major complications from the procedure among the 40.5% of patients discharged the same day relative to those who were discharged after at least one night in the hospital. In another study, drawn from a real-world prospective registry, outcomes were compared for potential candidates for same-day ablation on the basis of prespecified criteria and those who were not eligible for the procedure. These criteria included no bleeding history, a left ventricular ejection fraction greater than 40%, no pulmonary disease, and no surgical procedures within the previous 60 days. Of the 2332 patients included in the analysis, 1982 (85%) were deemed candidates for same-day ablation. Although freedom for atrial arrhythmias was comparable ( P = .0212) for the two groups, patients discharged the same day had a lower rate of complications (0.8% vs 2.9%; P < .001). The rate of readmission was similar (0.8% vs 09%; P = .924), according to the researchers. Contraindications for Same-Day Ablation In the document, relative contraindications for same-day ablation include decompensated heart failure, significant pulmonary disease, significant risk of bleeding, and any major unstable comorbidities such as diabetes, hypertension, or renal disease. The document recommends limiting same-day procedures to patients who can have readily available social support and can return to a hospital quickly in the event of a post-procedural complication. Acknowledging that most large hospitals offering ablation for AF already have formal selection criteria and protocols in place for same-day discharge, the authors called for free-standing sites to establish their own if they have not done so. In these settings, the authors emphasized the need to rigorously follow prespecified and 'ironclad' selection criteria and protocols. From this standpoint, Shankar said same-day procedures should always be performed on the basis of shared decision-making with the patient. While the economic benefits of same-day procedures might be shared by the facility and the patient, the latter should understand the inherent differences in the settings and participate actively in any decision of where the ablation is performed. Jones said while a substantial body of evidence supports same-day AF ablation as a safe and effective procedure that can free up necessary resources in the healthcare facility, the potential advantages are relevant only to appropriately selected patients. The new statement also suggests transfer agreements with inpatient facilities should be arranged in advance and that patients should be informed such a transfer is a possibility outside of a hospital setting. However, the document makes clear same-day ablations in alternative sites of care are reasonable when the precautions are observed. In any setting that AF ablation is performed, the writing committee encouraged tracking outcomes to ensure that high-quality care is achieved and sustained. Shankar and Jones reported no potential conflicts of interest.
Cision Canada
13-05-2025
- Business
- Cision Canada
Thryv Therapeutics to Share Recent Clinical Results and Participate in Upcoming Healthcare Investor Conferences
MONTREAL, May 13, 2025 /CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today announced its participation in two upcoming prominent investor conferences in New York City. The company will share recent clinical results in Long QT Syndrome presented at the 2025 Heart Rhythm Society Annual Meeting and recent developments for its pre-clinical and clinical programs for both heart failure and atrial fibrillation. Clinical Results Presented at HRS 2025 On April 27, 2025, Thryv presented new clinical data from Part 2 of the Wave I study at the Heart Rhythm Society (HRS) Annual Meeting. The study enrolled adult patients with genetically confirmed Long QT Syndrome Type 2 or Type 3 who received oral doses of LQT-1213 at either 7 mg TID or 16 mg TID for 2⅓ days (seven total doses). LQT-1213 appeared to be generally well-tolerated across both dose groups. Clinically meaningful and statistically significant reductions in QTcF interval were observed in the high dose cohort. Key regulatory endpoints for Long QT Syndrome – such as QTcF area under the curve (AUC) and maximal peak-to-trough effects – demonstrated mean reductions of up to 11 milliseconds (p=0.028) for QTcF AUC. In a subsequent analysis of peak-to-trough changes, the 53 milliseconds (p<0.0001) reduction in QTc is consistent with publications of other drugs studied but not approved for this indication. These results provide important clinical proof-of-concept that LQT-1213 – part of Thryv's series of highly selective SGK1 inhibitors – may offer a disease-modifying approach and lay the foundation for continued clinical development of SGK1 Inhibitors for Long QT Syndrome. Upcoming Investor Conferences RBC Capital Markets Global Healthcare Conference 2025 Dates: May 20–21, 2025 Fireside Chat: Wednesday, May 21, 2025, at 9:30 am EST (Track IV – 2 nd Floor) Location: InterContinental New York Barclay, New York, NY Thryv Therapeutics will participate in a fireside chat and host one-on-one meetings with investors about its future program plans and Series B financing throughout the conference. Jefferies Global Healthcare Conference 2025 Dates: June 3–5, 2025 Location: New York Marriott Marquis, New York, NY Thryv Therapeutics will participate in one-on-one investor meetings. To request a meeting at either conference, please contact: [email protected] Study Highlights Wave I is a multi-part, first-in-human proof-of-concept clinical study designed to evaluate the safety, pharmacokinetics (PK), and efficacy of LQT-1213 in patients with both acquired and congenital forms of Long QT Syndrome. Part 1 results were presented at the American College of Cardiology's Annual Scientific Session in March 2024. Read the full poster here. Part 2 is a single-blind, placebo run-in, multiple-dose safety study in participants with cLQTS Type 2 or 3. Results were presented at the Heart Rhythm Society Annual Meeting in April 2025. Read the full abstract here. More about the Wave I study (Parts 1 and 2) can be found at: About Thyrv's SGK1 Inhibitors Thryv Therapeutics is advancing a series of potent and selective SGK1 (serum and glucocorticoid-regulated kinase 1) inhibitors that target the underlying causes of electrical and structural remodelling which leads to cardiac conditions such as Long QT Syndrome, heart failure, and atrial fibrillation. In heart tissue, SGK1 has been shown to adversely affect ion channel function and surface expression. Its activation is implicated in prolongation of the QT interval, contributing to both congenital and acquired forms of LQTS and adverse outcomes in cardiometabolic diseases such as heart failure and atrial fibrillation. Inhibition of SGK1 may address the root cause of electrical dysfunction and offer a disease-modifying therapy by targeting both electrical and structural remodeling of cardiomyocytes. About Long QT Syndrome (LQTS) Long QT Syndrome (LQTS) is a disorder of the heart's electrical system that delays ventricular repolarization, prolonging the QT interval on an ECG. This can lead to torsade de pointes — a potentially fatal arrhythmia — and sudden cardiac death. LQTS can be congenital, caused by mutations in cardiac ion channel genes (commonly LQT1, LQT2, or LQT3), or acquired, resulting from medications or medical conditions. Congenital LQTS is a rare orphan disease, affecting approximately 1 in 2,000 people worldwide. About Thryv Therapeutics Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat Long QT Syndrome, heart failure and atrial fibrillation with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1). For more information, please visit
Yahoo
05-05-2025
- Business
- Yahoo
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE Mark Study confirm the long-term safety and efficacy of the Volt PFA System The data were presented at the 2025 Heart Rhythm Society (HRS) annual meeting ABBOTT PARK, Ill., April 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System for the treatment of atrial fibrillation (AFib). The data also highlights the excellent safety profile of the Volt PFA System alongside the system's ability to achieve results with fewer therapy applications (just 4.7 applications per vein on average) than on-market competitive PFA systems. PFA therapy works differently from traditional cardiac ablation approaches by delivering high energy electrical pulses to targeted areas of cardiac tissue causing abnormal heart rhythms. Abbott designed its Volt CE Mark Study to assess the impact of the Volt PFA System in two different patient groups – people battling paroxysmal atrial fibrillation (PAF) - episodes that come and go - as well as persistent AFib (PersAF) - episodes that last longer than seven days. The 12-month data from the Volt CE Mark Study were presented at the 2025 Heart Rhythm Society (HRS) annual meeting held in San Diego (April 24-27, 2025) and simultaneously published in Heart Rhythm, the official journal of the Heart Rhythm Society. Sustained Performance of the Volt PFA SystemData from the Volt CE Mark Study showed that after 12 months, Abbott's Volt PFA System delivered: Outstanding long-term performance. The Volt PFA System demonstrated sustained performance in both safety and effectiveness out to 12 months for patients with PAF and PersAF. Freedom from arrhythmia. 83.5% of PAF patients and 58.1% of PersAF patients remained free from atrial arrhythmia after 12 months – one of the lowest rates of reoccurrence in PAF patients in a long-term PFA study to date. Quality of life (QoL) benefits. After 12 months, the Volt CE Mark Study showed a significant QoL benefit for patients, with QoL assessment scores improving from 64.1 to 88.1. Excellent safety profile. After 12 months, just 2.7% of Volt patients had experienced a primary safety endpoint event with zero patients suffering from hemolysis (destruction of red blood cells), coronary artery spasm, pulmonary vein stenosis, acute kidney injury, or phrenic nerve injury – all potential challenges of PFA therapy. "The long-term 12-month results from the Volt CE Mark Study paint a picture of a PFA system that performs exceptionally well in two different groups of patients – each with unique therapy needs and clinical approaches," said Prof. Gian-Battista Chierchia, director of the Atrial Fibrillation Program at the Heart Rhythm Management Institute at the University of Brussels in Belgium. "These long-term data provide us a strong picture of how the Volt PFA System will perform in clinical settings as we leverage PFA therapy for our patients." To date, clinical experience following CE Mark has further confirmed that the Volt PFA System can support treating patients battling either PAF or PersAF, allowing the system to help as many patients as possible. The Volt PFA System also provides a single-catheter PFA approach, improves workflow and provides procedural flexibility by allowing for light sedation or general anesthesia. A new sub-analysis from the VOLT-AF IDE Study presented at HRS 2025 showed no significant difference in safety or acute effectiveness outcomes in cases performed under conscious or deep sedation when compared to procedures performed with general anesthesia. "Our goal from the beginning with the Volt PFA System was to design a PFA system that would provide outstanding results in patients battling a range of atrial arrhythmias, and the latest data from the Volt CE Mark Study is confirmation that the system will truly impact patient care in a positive way," said Christopher Piorkowski, M.D., chief medical officer of Abbott's electrophysiology business. About the Volt CE Mark StudyAbbott's Volt CE Mark Study is a prospective, single-arm, non-randomized, multicenter study designed to demonstrate the safety and effectiveness of the Volt PFA System for the treatment of symptomatic, recurrent, drug-refractory PAF and PersAF. The study enrolled 150 patients at 11 sites across Europe and included a feasibility sub-study in which additional imaging assessments were collected to confirm the acute safety of the Volt PFA System. About AbbottAbbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at and on LinkedIn, Facebook, Instagram, X and YouTube. View original content: SOURCE Abbott
Yahoo
29-04-2025
- Health
- Yahoo
Investigational data presented at Heart Rhythm Society demonstrates promising multi-sensing capabilities of SANSA home sleep apnea test
SAN DIEGO, April 29, 2025 /PRNewswire/ -- Huxley Medical unveiled promising investigational data from the company's SANSA monitoring platform at the Heart Rhythm Society meeting, held in San Diego from April 24-27. In the observational study, investigators evaluated the feasibility of SANSA to simultaneously assess sleep apnea, arrhythmia, and activity patterns. The study highlights the high burden of unrecognized sleep apnea in electrophysiology populations and the breadth of insights the SANSA multi-sensing platform is capable of generating from a single use. With continued development, researchers believe SANSA could simplify diagnostic workflows for complex patients and enhance cross-specialty collaboration between cardiology, electrophysiology, and sleep medicine. Key findings from the research: Previously unrecognized sleep apnea was detected in 67% (20/30) of electrophysiology patients being monitored for arrhythmias SANSA revealed sleep apnea during a daytime nap as well as overnight sleep, highlighting how typical overnight-only home sleep apnea testing may miss the full burden of disease and not capture valuable information about patients' circadian sleep patterns Simultaneous collection of ECG alongside oximetry, motion, and respiration provided valuable context to understand relationships between arrhythmia burden, sleep, and activity level The research team leading the study suggested that unifying the assessment of sleep-disordered breathing and cardiac arrhythmias could provide valuable insight into disease states and inform clinical management of complex patients. Rohit Mehta, MD, cardiac electrophysiologist at the Sanger Heart and Vascular Institute and Professor of Medicine at Wake Forest University School of Medicine, said, "A key unmet need in current diagnostic assessments is the ability to contextualize when disease occurs and to identify how different disease states influence one another. This is particularly true for frequently comorbid conditions like various arrhythmias and sleep apnea. A unified assessment could help tailor disease management for the patient and allow more specific and appropriate therapies to be provided. This study suggests promising potential for SANSA to help address this need and motivates continued clinical research and validation." Samuel Sears, PhD, ABPP, professor of cardiovascular sciences and psychology at East Carolina University and division chief of innovation and research for the East Carolina Heart Institute, added "Keeping patients active and understanding how their heart responds to physical activity is one of the most critical things we can do for our cardiac patients. Devices like SANSA that provide this level of information alongside standard Holter data could become the standard." Researchers also highlighted the promise of SANSA to streamline workflows and strengthen how different clinical specialties work together to provide care. Douglas Kirsch, MD, Medical Director of Sleep Medicine at Atrium Health and Clinical Professor of Neurology at Wake Forest University School of Medicine, said, "Siloed workflows create complexity for patients and hamper inter-specialty collaboration. Devices with muti-diagnostic capabilities, like SANSA, may enable faster and more efficient approaches to patients where both sleep and cardiac disorders are suspected." About Huxley Medical Huxley Medical, Inc. is a privately held medical technology company on a mission to develop diagnostic solutions that streamline care for any patient anywhere. The company has received funding from the National Science Foundation, National Institutes of Health, Georgia Research Alliance Venture Fund, Invest Georgia, Georgia Tech Foundation Research Impact Fund, and Duke Capital Partners to translate its growing technology portfolio. To learn more, visit or email info@ Research abstract: "Simultaneously Monitoring Patterns of Arrhythmia, Sleep Apnea, and Activity with a Single Chest-worn Device" Media Contact: Brennan Torstrick Chief Scientific Officer Huxley Medical View original content to download multimedia: SOURCE Huxley Medical, Inc. Sign in to access your portfolio
Business Insider
28-04-2025
- Health
- Business Insider
Medtronic announces outcomes from two studies in AFib patients
Medtronic (MDT) announced positive clinical outcomes from two studies in atrial fibrillation, AFib, patients treated with the Affera family of technologies, including the next-generation Sphere-360 single-shot pulsed field ablation catheter and the groundbreaking Sphere-9 combination mapping and dual-energy focal PFA catheter. Data were presented in High Impact Science Sessions at the Heart Rhythm Society 2025 Annual Meeting in San Diego; the Sphere-360 study was simultaneously published in the Heart Rhythm Journal. The company said; One-year clinical trial data for the next-generation, investigational, Sphere-360 single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib; Dual-energy, focal Sphere-9 catheter demonstrates efficacy for linear ablation in persistent AFib; Medtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual meeting Stay Ahead of the Market:
